Nearly 70 players from across the world presently claim to be engaged in the development and evaluation of therapeutic candidates based on a number of psychedelic compounds, such as ketamine and psilocybin, claims Roots Analysis

Market-Research

Psychedelic substances have been demonstrated to interact with a variety of neurotransmitter pathways, including those involving serotonin, acetylcholine, norepinephrine, and dopamine. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of psychedelic substances. Further, experts believe that psychedelics, at appropriate doses, can be used to address some of the serious psychological implications associated with the COVID-19 pandemic.

To order this 250+ page report, which features 120+ figures and 135+ tables, please visit this link

The over USD 6.5 billion (by 2030) financial opportunity within the psychedelic therapeutics market has been analyzed across the following segments:

Target Disease Indication

Anxiety and Depression
Trauma
Pain Disorder
Sleep related Disorder

Origin of Psychedelic Substance
Natural
Synthetic

Type of Psychedelic Substance
Gamma-hydroxybutyrate
Ketamine
MDMA
Psilocybin

Route of Administration
Oral
Intranasal
Sublingual

Key Geographies
North America
Europe
Asia-Pacific

The Global Psychedelic Therapeutics Market, 2020-2030 report features the following companies, which we identified to be key players in this domain: